Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers July 01, 2022 From AstraZeneca Via Business Wire Tickers AZN PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence June 21, 2022 From AstraZeneca Via Business Wire Tickers AZN Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) June 21, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease June 05, 2022 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial June 04, 2022 From AstraZeneca Via Business Wire Tickers AZN First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis May 27, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022 May 23, 2022 From AstraZeneca Via Business Wire Tickers AZN PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma May 15, 2022 From AstraZeneca Via Business Wire Tickers AZN FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction May 05, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen May 05, 2022 From AstraZeneca Via Business Wire Tickers AZN ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder May 05, 2022 From AstraZeneca Via Business Wire Tickers AZN Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial May 04, 2022 From AstraZeneca Via Business Wire Tickers AZN ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis April 28, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer April 27, 2022 From AstraZeneca Via Business Wire Tickers AZN Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi April 25, 2022 From AstraZeneca Via Business Wire Tickers AZN EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations April 20, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer April 19, 2022 From AstraZeneca Via Business Wire Tickers AZN ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks April 06, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees March 24, 2022 From AstraZeneca Via Business Wire Tickers AZN EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies March 21, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer March 16, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer February 21, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer February 14, 2022 From AstraZeneca Via Business Wire Tickers AZN Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis January 24, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years January 18, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer January 18, 2022 From AstraZeneca Via Business Wire Tickers AZN CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen January 17, 2022 From AstraZeneca Via Business Wire Tickers AZN Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen January 17, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU January 13, 2022 From AstraZeneca Via Business Wire Tickers AZN TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma January 13, 2022 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.